490 BioTech receives NIH Phase II SBIR award for improving drug discovery screens and 3D microphysiological assays

490 BioTech is pleased to announce the acquisition of a Phase II SBIR award from the National Institutes of Health, National Institute of General Medical Sciences for the development of new high-throughput drug discovery screens that are more predictive of pharmacological safety and toxicity. Using our autobioluminescent expression system, we will create novel data-intensive, autonomous,…

490 BioTech partners with Applied StemCell for new regenerative medicine in vivo models

  490 BioTech is pleased to announce a Phase II STTR award from the National Institutes of Health, National Institute of General Medical Sciences, that will enable the development of novel in vitro cellular and in vivo rodent models endowed with our patented autobioluminescent expression technology for the continuous and non-invasive surveillance of stem cell…